The Vertical Group
VC Fund
Basking Ridge, United States
The Vertical Group is a New Jersey-based venture capital firm focused on the fields of medical technology and biotechnology.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 11%
- Fund size:
- $10M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries The Vertical Group invests in
Stages The Vertical Group invests in
Countries The Vertical Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series B
- $5M–$60M
- Series C
- $1.5M–$77M
Investment Focus
Industry
- Health Care 28 (40%)
- Medical Device 18 (26%)
- Medical 16 (23%)
- Biotechnology 15 (21%)
- Therapeutics 6 (9%)
Stage
- Series B 15 (21%)
- Series C 11 (16%)
- Funding Round 10 (14%)
- Series A 9 (13%)
- Series D 5 (7%)
Country
- United States 33 (47%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jack W. Lasersohn
General Partner
|
General Partner | Total investments: 12 | Find email | |
John E. Runnells
General Partner
|
General Partner | Total investments: 0 | Find email | |
Richard B. Emmitt
Founder/Managing Director
|
Founder/Managing Director | Total investments: 2 | Find email | |
Tony Chou
General Partner
|
General Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Route 92 Medical
|
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M / Private Equity / Apr 07, 2026 | |
Mobia Medical
|
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $65M / Series F / Mar 12, 2025 | |
|
Route 92 Medical
|
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $50M / Series F / Sep 23, 2024 | |
|
Route 92 Medical
|
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $31M / Series F / Nov 16, 2023 | |
Luminopia
|
Luminopia develops a new class of treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, totreat amblyopia, the cause of vision loss among children. | $16M / Series A / Jun 27, 2023 | |
|
Luminopia
|
Luminopia develops a new class of treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, totreat amblyopia, the cause of vision loss among children. | $5.7M / Seed / Oct 19, 2022 | |
|
Mobia Medical
|
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $73M / Series E / Jun 20, 2022 | |
Carlsmed
|
Provider of medical technology for spine surgery. The company’s proprietary aprevo™ digital-to-device 3-D printed implant system for spine is first-ever surgical implant to be designated by the FDA as a breakthrough technology. Hospital and surgeon customers across the country choose aprevo™ for the benefits of personalized medicine in lumbarfusion surgery.Carlsmed was founded in 2018 and is headquartered in San Diego, California. | $30M / Series B / Apr 19, 2022 | |
|
Route 92 Medical
|
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. | $56M / Series E / Dec 14, 2021 | |
|
Carlsmed
|
Provider of medical technology for spine surgery. The company’s proprietary aprevo™ digital-to-device 3-D printed implant system for spine is first-ever surgical implant to be designated by the FDA as a breakthrough technology. Hospital and surgeon customers across the country choose aprevo™ for the benefits of personalized medicine in lumbarfusion surgery.Carlsmed was founded in 2018 and is headquartered in San Diego, California. | $10M / Series A / Dec 16, 2020 | |
| See all 70 investments → | |||
Co-Investors
U.S. Venture Partners
19 deals together
Latterell Venture Partners
12 deals together
Warburg Pincus
10 deals together
DeNovo Ventures
7 deals together
Morgenthaler Ventures
5 deals together
Norwest
5 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does The Vertical Group invest in?
The Vertical Group invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series C stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The Vertical Group's check size?
The Vertical Group typically joins rounds of $5M–$60M at Series B and $1.5M–$77M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Vertical Group participates in.
How do I contact The Vertical Group?
Public channels for The Vertical Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Vertical Group?
The team at The Vertical Group includes Jack W. Lasersohn (General Partner), John E. Runnells (General Partner) and Richard B. Emmitt (Founder/Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
